Similar articles for PMID: 17011081

Year	Number of Results
1919	1
1980	2
1983	1
1986	1
1987	1
1988	1
1989	1
1990	3
1991	1
1993	1
1995	2
2002	1
2004	2
2005	6
2006	4
2007	2
2008	3
2009	2
2010	2
2011	7
2012	13
2013	12
2014	5
2015	6
2016	4
2017	6
2018	8
2019	4
2021	4
2022	2
2023	2
2024	0

1

[Economic evaluation of at home subcutaneous and intravenous immunoglobulin substitution].

Haddad L, Perrinet M, Parent D, Leroy-Cotteau A, Toguyeni E, Condette-Wojtasik G, Hachulla E. Haddad L, et al. Rev Med Interne. 2006 Dec;27(12):924-6. doi: 10.1016/j.revmed.2006.08.005. Epub 2006 Sep 18. Rev Med Interne. 2006. PMID: 17011081 French.

2

Clinical Profile, Dosing, and Quality-of-Life Outcomes in Primary Immune Deficiency Patients Treated at Home with Immunoglobulin G: Data from the IDEaL Patient Registry.

Kearns S, Kristofek L, Bolgar W, Seidu L, Kile S. Kearns S, et al. J Manag Care Spec Pharm. 2017 Apr;23(4):400-406. doi: 10.18553/jmcp.2017.23.4.400. J Manag Care Spec Pharm. 2017. PMID: 28345437 Free PMC article.

3

[Subcutaneous immunoglobulin and support program: what level of interest of patients?].

Bourdin A, Berger J, Früh A, Spertini F, Bugnon O. Bourdin A, et al. Rev Med Suisse. 2015 Apr 8;11(469):831-5. Rev Med Suisse. 2015. PMID: 26040165 French.

4

Pharmacoeconomics of immunoglobulins in primary immunodeficiency.

Simoens S. Simoens S. Expert Rev Pharmacoecon Outcomes Res. 2009 Aug;9(4):375-86. doi: 10.1586/erp.09.37. Expert Rev Pharmacoecon Outcomes Res. 2009. PMID: 19670998 Review.

5

Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies.

Dams ET, van der Meer JW. Dams ET, et al. Lancet. 1995 Apr 1;345(8953):864. doi: 10.1016/s0140-6736(95)93002-7. Lancet. 1995. PMID: 7898254 Free article. No abstract available.

6

Managing cost of care and healthcare utilization in patients using immunoglobulin agents.

Vaughan LJ. Vaughan LJ. Am J Manag Care. 2019 Jun;25(6 Suppl):S105-S111. Am J Manag Care. 2019. PMID: 31318516 Free article.

7

Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review.

Lingman-Framme J, Fasth A. Lingman-Framme J, et al. Drugs. 2013 Aug;73(12):1307-19. doi: 10.1007/s40265-013-0094-3. Drugs. 2013. PMID: 23861187 Review.

8

[IgIV at home:experience of a center--economic aspects].

Hachulla E. Hachulla E. Rev Med Interne. 2007 May;28 Spec No. 1:7-10. Rev Med Interne. 2007. PMID: 17768832 Review. French.

9

Switching Patients to Home-Based Subcutaneous Immunoglobulin: an Economic Evaluation of an Interprofessional Drug Therapy Management Program.

Perraudin C, Bourdin A, Spertini F, Berger J, Bugnon O. Perraudin C, et al. J Clin Immunol. 2016 Jul;36(5):502-10. doi: 10.1007/s10875-016-0288-z. Epub 2016 May 2. J Clin Immunol. 2016. PMID: 27139500

10

Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies.

Beauté J, Levy P, Millet V, Debré M, Dudoit Y, Le Mignot L, Tajahmady A, Thomas C, Suarez F, Pellier I, Hermine O, Aladjidi N, Mahlaoui N, Fischer A; French PID study group CEREDIH. Beauté J, et al. Clin Exp Immunol. 2010 May;160(2):240-5. doi: 10.1111/j.1365-2249.2009.04079.x. Epub 2009 Dec 16. Clin Exp Immunol. 2010. PMID: 20041884 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

102 results

Results by year